The startup develops personalized T-cell therapies that target solid tumors, utilizing engineered T-cells to elicit a durable immune response. Their treatments aim to inhibit tumor growth and improve patient outcomes in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors pose a significant challenge in oncology due to their complex microenvironment and resistance to conventional therapies. Current treatment options often fail to elicit a durable immune response, leading to tumor recurrence and poor patient outcomes. The need for more effective and targeted therapies remains unmet.
Solution
This startup is developing personalized T-cell therapies designed to target and eliminate solid tumors. Their approach involves engineering a patient's own T-cells to recognize and attack specific antigens present on tumor cells. By modifying T-cells to express chimeric antigen receptors (CARs) or enhanced T-cell receptors (TCRs), the therapy aims to overcome the tumor's defenses and induce a robust, sustained anti-tumor immune response. The engineered T-cells are then infused back into the patient, where they actively seek out and destroy cancer cells, potentially leading to tumor regression and improved survival rates. This personalized approach allows for tailored treatments that address the unique characteristics of each patient's tumor.
Target Audience
The primary target audience includes oncology patients with solid tumors who have failed to respond to standard treatments, as well as oncologists and medical centers specializing in immunotherapy.
Features
- Personalized T-cell engineering using CAR or enhanced TCR technology
- Targeting of specific tumor-associated antigens to minimize off-target effects
- Enhanced T-cell activation and proliferation for a potent immune response
- Proprietary methods to overcome the immunosuppressive tumor microenvironment
- Streamlined manufacturing process for rapid T-cell production and delivery